Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 4/2011

01-12-2011 | Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Substance Use: Impact on Adherence and HIV Medical Treatment

Authors: Adam Gonzalez, Jennifer Barinas, Conall O’Cleirigh

Published in: Current HIV/AIDS Reports | Issue 4/2011

Login to get access

Abstract

Substance use is highly prevalent among people living with HIV/AIDS, is often comorbid with other mental health problems, related to poor HIV medical outcomes, and, is associated with poor medication and treatment adherence. The current review reports on the recent state of the literature in terms of substance use and its relation to HIV medication and treatment adherence, and offers recommendations for advancing treatment and secondary HIV prevention efforts. Identifying substance users within HIV primary care and developing, evaluating, and refining integrative substance use-mental health-adherence interventions may be clinically important targets for effective disease management and may contribute to secondary HIV prevention efforts.
Literature
1.
Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006;41:194–200.PubMedCrossRef
2.
Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22–9.PubMedCrossRef
3.
Parruti G, Manzoli L, Marani Toro P, et al. Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse. AIDS Patient Care STDS. 2006;20:48–56.PubMedCrossRef
4.
Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:11–9.PubMedCrossRef
5.
Low-Beer S, Yip B, O’Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360–1.PubMedCrossRef
6.
Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.PubMed
7.
•• HIV Prevention Trials Network (HPTN-052). Initiation of antiretroviral treatment protects uninfected sexual partners from HIV infection (HPTN Study 052). Press Release May 12 2011. http://​www.​hptn.​org/​index.​htm. This is the first randomized clinical trial to demonstrate that treating an HIV-infected person early with ART, compared to delayed initiation, can reduce the risk of sexual transmission for partners without HIV.
8.
Bing EG, Burnam MA, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry. 2001;58:721–8.PubMedCrossRef
9.
McGowan CC, Weinstein DD, Samenow CP, et al. Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS ONE. 2011;6:e18462.PubMedCrossRef
10.
Rabkin JG, McElhiney MC, Ferrando SJ. Mood and substance use disorders in older adults with HIV/AIDS: methodological issues and preliminary evidence. AIDS. 2004;18:S43–8.PubMedCrossRef
11.
Treisman G, Angelino A. Interrelation between psychiatric disorders and the prevention and treatment of HIV infection. Clin Infect Dis. 2007;45:S313–7.PubMedCrossRef
12.
13.
Gaynes BN, Pence BW, Eron JJ, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med. 2008;70:505–11.PubMedCrossRef
14.
Amsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–81.
15.
King WD, Larkins S, Hucks-Ortiz C, et al. Factors associated with HIV viral load in a respondent driven sample in Los Angeles. AIDS Behav. 2009;13:145–53.PubMedCrossRef
16.
Lucas GM, Cheever LW, Chaison RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251–9.PubMedCrossRef
17.
•• Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010;112:178–93. A review of the literature that indicates among persons with HIV/AIDS, alcohol use disorders are related to decreased ART adherence and to poorer HIV treatment outcomes.PubMedCrossRef
18.
Friedman MS, Marshal MP, Stall R, et al. Associations between substance use, sexual risk taking and HIV treatment adherence among homeless people living with HIV. AIDS Care. 2009;21:692–700.PubMedCrossRef
19.
•• Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr. 2009;52:180–202. This is a meta-analysis of 40 studies indicating that alcohol users with HIV/AIDS are only 47%–60% as likely to be adherent to ART than non-users.PubMedCrossRef
20.
Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103:1242–57.PubMedCrossRef
21.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (revised 4th ed.). Washington DC; 2000.
22.
Gruber VA, Sorensen JL, Haug NA. Psychosocial predictors of adherence to highly active antiretroviral therapy practical implications. J HIV AIDS Soc Serv. 2007;6:23–37.CrossRef
23.
•• Sandelowski M, Voils CI, Chang Y, Lee EJ. A systematic review comparing antiretroviral adherence descriptive and intervention studies conducted in the USA. AIDS Care. 2009;21:953–66. This is a review of 88 studies examining facilitators and barriers related to ART adherence, which highlights substance abuse as a significant barrier to adherence.PubMedCrossRef
24.
Malta M, Magnanini MMF, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010;14:731–47.PubMedCrossRef
25.
Heffelfinger JD, Voetsch AC, Nakamura GV, et al. Nonadherence to primary prophylaxis against Pneumocystis jirovecii pneumonia. PLoS ONE. 2009;4:e5002.PubMedCrossRef
26.
Amuha MG, Kutyabami P, Kitutu FE, et al. Non-adherence to anti-TB drugs among TB/HIV co-infected patients in Mbarara Hospital Uganda: prevalence and associated factors. Afr Health Sci. 2009;9:S8–S15.PubMed
27.
Conover CJ, Weaver M, Ang A, et al. Costs of care for people living with combined HIV/AIDS, chronic mental illness, and substance abuse disorders. AIDS Care. 2009;21:1547–59.PubMedCrossRef
28.
•• Mellins CA, Havens JF, McDonnell C, et al. Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders. AIDS Care. 2009;21:168–77. Data from 1138 adults with HIV/AIDS and comorbid mental and substance abuse disorders indicated that ART nonadherence was related to current alcohol and drug abuse, increased psychological distress, less attendance at medical appointments, nonadherence to psychiatric medication, and lower self-reported spirituality. PubMedCrossRef
29.
Chander G, Himelhoch S, Fleishman JA, et al. HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care. 2009;21:655–63.PubMedCrossRef
30.
When to start consortium et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-indected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352–63.CrossRef
31.
Giordano TP, Gifford AL, White Jr AC, et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis. 2007;44:1493–9.PubMedCrossRef
32.
Metsch LR, Bell C, Pereyra M, et al. Hospitalized HIV-infected patients in the era of highly active antiretroviral therapy. Am J Public Health. 2009;99:1045–9.PubMedCrossRef
33.
Josephs JS, Fleishman JA, Korthuis PT, et al. Emergency department utilization among HIV-infected patients in a multisite multistate study. HIV Med. 2010;11:74–84.PubMedCrossRef
34.
Meade CS, Hansen NB, Kochman A, Sikkema KJ. Utilization of medical treatments and adherence to antiretroviral therapy among HIV-positive adults with histories of childhood sexual abuse. AIDS Patient Care STDS. 2009;23:259–66.PubMedCrossRef
35.
Ulett KB, Willig JH, Routman JS, et al. The therapeutic implications of timely linkage and early retention in HIV Care. AIDS Patient Care STDS. 2009;23:41–9.PubMedCrossRef
36.
Hessol NA, Weber KM, Holman S, et al. Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States. J Womens Health. 2009;18:1627–37.CrossRef
37.
Sohler NL, Coleman SM, Cabral H, et al. Does self-report data on HIV primary care utilization agree with medical record data for socially marginalized populations in the United States? AIDS Patient Care STDS. 2009;23:837–43.PubMedCrossRef
38.
Michel L, Carrieri MP, Fugon L, et al. Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANS-EN12-VESPA Study): relevance for clinical management and intervention. AIDS Care. 2010;22:1136–45.PubMedCrossRef
39.
Baum MK, Rafie C, Lai S, et al. Alcohol use accelerates HIV disease progression. AIDS Res Hum Retroviruses. 2010;26:511–8.PubMedCrossRef
40.
Iralu J, Duran B, Pearson CR, et al. Risk factors for HIV disease progression in a rural southwest American Indian population. Public Health Rep. 2010;125:43–50.PubMed
41.
Shuper PA, Neuman M, Kanteres F, et al. Causal considerations on alcohol and HIV/AIDS—a systematic review. Alcohol Alcohol. 2010;45:159–66.PubMed
42.
Neblett RC, Hutton HE, Lau B, et al. Alcohol consumption among HIV-infected women: impact on time to antiretroviral therapy and survival. J Womens Health. 2011;20:279–86.CrossRef
43.
Cheng DM, Libman H, Bridden C, et al. Alcohol consumption and lipodystrophy in HIV-infected adults with alcohol problems. Alcohol. 2009;43:65–71.PubMedCrossRef
44.
Farley J, Miller E, Zamani A, et al. Screening for hazardous alcohol use and depressive symptomatology among HIV-infected patients in Nigeria: prevalence, predictors, and association with adherence. J Int Assoc Physicians AIDS Care. 2010;9:218–26.CrossRef
45.
• Miguez-Burbano MJ, Lewis JE, Fishman J, et al. The influence of different types of alcoholic beverages on disrupting highly active antiretroviral treatment (HAART) outcome. Alcohol. 2009;44:366–71. This study showed that among people with HIV/AIDS, consuming liquor only (compared to beer or wine only) is related to poor CD4 T-cell production and poor viral suppression.CrossRef
46.
Conen A, Fehr J, Glass TR, et al. Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV cohort study. Antivir Ther. 2009;14:349–57.PubMed
47.
Glass TR, Battegay M, Cavassini M, et al. Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV cohort study. J Acquir Immune Defic Syndr. 2010;54:197–203.PubMed
48.
Outlaw A, Naar-King S, Green-Jones M, et al. Predictors of optimal HIV appointment adherence in minority youth: a prospective study. J Pediatr Psychol. 2010;35:1011–5.PubMedCrossRef
49.
Beyene KA, Gedif T, Gebre-Mariam T, Engidawork E. Highly active antiretroviral therapy adherence and its determinants in selected hospitals from south and central Ethiopia. Pharmacoepidemiol Drug Saf. 2009;18:1007–15.PubMedCrossRef
50.
Bhat VG, Ramburuth M, Singh M, et al. Factors associated with poor adherence to anti-retroviral therapy in patients attending a rural health centre in South Africa. Eur J Clin Microbiol Infect Dis. 2010;29:947–53.PubMedCrossRef
51.
Do NT, Phiri K, Bussmann H, et al. Psychosocial factors affecting medication adherence among HIV-1 infected adults receiving combination antiretroviral therapy (cART) in Botswana. AIDS Res Hum Retroviruses. 2010;26:685–91.PubMedCrossRef
52.
Fitzgerald M, Collumbien M, Hosegood V. “No one can ask me ‘Why do you take that stuff?’”: men’s experiences of antiretroviral treatment in South Africa. AIDS Care. 2010;22:355–60.PubMedCrossRef
53.
Jaquet A, Ekouevi DK, Bashi J, et al. Alcohol use and non-adherence to antiretroviral therapy in HIV-infected patients in West Africa. Addiction. 2010;105:1416–21.PubMedCrossRef
54.
Protopopescu C, Raffi F, Roux P, et al. Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother. 2009;64:599–606.PubMedCrossRef
55.
Silva MCF, Ximenes RAA, Filho DBM, et al. Risk-factors for non-adherence to antiretroviral therapy. Rev Inst Med Trop S Paulo. 2009;51:135–9.PubMedCrossRef
56.
Kalichman SC, Amaral CM, White D, et al. Prevalence and clinical implications of interactive toxicity beliefs regarding mixing alcohol and antiretroviral therapies among people living with HIV/AIDS. AIDS Patient Care STDS. 2009;23:449–54.PubMedCrossRef
57.
Strauss SM, Tiburcio NJ, Munoz-Plaza C, et al. HIV care providers’ implementation of routine alcohol reduction support for their patients. AIDS Patient Care STDS. 2009;23:211–8.PubMedCrossRef
58.
Velasquez MM, von Sternberg K, Johnson DH. Reducing sexual risk behaviors and alcohol use among HIV-positive men who have sex with men: a randomized clinical trial. J Consult Clin Psychol. 2009;77:657–67.PubMedCrossRef
59.
Papas RK, Sidle JE, Martino S, et al. Systematic cultural adaptation of cognitive-behavioral therapy to reduce alcohol use among HIV infected outpatients in Western Kenya. AIDS Behav. 2010;14:669–78.PubMedCrossRef
60.
Parsons JT, Golub SA, Rosof E, Holder C. Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers a randomized controlled trial. J Acquir Immune Defic Syndr. 2007;46:443–50.PubMedCrossRef
61.
Longmire-Avital B, Golub SA, Parsons JT. Self-reevaluation as a critical component in sustained viral load change in HIV+ adults with alcohol problems. Ann Behav Med. 2010;40:176–83.PubMedCrossRef
62.
Bouhnik AD, Chesney M, Carrieri P, et al. Nonadherence among HIV-infected injecting drug users: the impact of social instability. J Acquir Immune Defic Syndr. 2002;31:S149–53.PubMedCrossRef
63.
Mehta SH, Lucas G, Astemborski J, et al. Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care. 2007;19:637–45.PubMedCrossRef
64.
Koester S, Glanz J, Barón A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav. 2005;9:27–39.PubMedCrossRef
65.
Rhodes T, Sarang A, Bobrik A, et al. HIV transmission and HIV prevention associated with injecting drug use in the Russian Federation. Int J Drug Policy. 2004;15:1–16.CrossRef
66.
Hernández SO, Martín LL, Isabel JAC, et al. Drug use and antiretroviral adherence in methadone maintenance patients: a longitudinal study. Int J Psychol Psychol Ther. 2009;9:365–81.
67.
Kresina TF, Bruce RD, McCance-Katz EF. Medication assisted treatment in the treatment of drug abuse and dependence in HIV/AIDS infected drug users. Curr HIV Res. 2009;7:354–64.PubMedCrossRef
68.
Lucas GM, Chaudhry A, Hsu J, et al. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: a randomized trial. Ann Intern Med. 2010;152:704–11.PubMed
69.
Wang H, Zhou J, Huang L, et al. Effects of nurse-delivered home visits combined with telephone calls on medication adherence and quality of life in HIV-infected heroin users in Hunan of China. J Clin Nurs. 2010;19:380–8.PubMedCrossRef
70.
Safren SA, O’Cleirigh C, Bullis JR. CBT for adherence and depression (CBT-AD) in HIV-infected injection drug users: an RCT. J Consult Clin Psychol. 2011;Under review.
71.
Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18:262–70.PubMedCrossRef
72.
Hinkin CH, Barclay TR, Castellon SA, et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11:185–94.PubMedCrossRef
73.
Sharpe TT, Lee LM, Nakashima AK, et al. Crack cocaine use and antiretroviral treatment among HIV-infected Black women. J Commun Health. 2004;29:117–27.CrossRef
74.
Duncan R, Shapshak P, Page JB, et al. Crack cocaine: effect modifier of RNA viral load and CD4 count in HIV-infected African American women. Front Biosci. 2007;12:1488–95.PubMedCrossRef
75.
Carrico AW, Johnson MO, Morin SF, et al. Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy. Brain Behav Immun. 2008;22:1257–62.PubMedCrossRef
76.
•• Baum M, Rafie C, Lai S, et al. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr. 2009;50:93–9. This study found that crack-cocaine users compared to non-users with HIV/AIDS were 2.14 times more likely to have a CD4 T-cell count decline to 200 cells/mL or below, and have a higher HIV viral load, independent of ART use.PubMedCrossRef
77.
Meade CS, Conn NA, Skalski LM, Safren SA. Neurocognitive impairment and medication adherence in HIV patients with and without cocaine dependence. J Behav Med. 2011;34:128–38.PubMedCrossRef
78.
Bell C, Metsch LR, Vogenthaler N, et al. Never in care: characteristics of HIV-infected crack cocaine users in 2 US cities who have never been to outpatient HIV care. J Acquir Immune Defic Syndr. 2010;54:376–80.PubMed
79.
Traeger L, O’Cleirigh C, Perry N, Bedoya CA, Safren SA. Does Substance use interfere with acquisition and maintenance of HIV medication adherence skills? Poster presented at the International Association of Physicians in AIDS Care (IAPAC) 6th Annual International Conference on HIV Treatment and Prevention Adherence. Miami Beach, FL; May 22–24, 2011.
80.
Meade CS, Drabkin AS, Hansen NB, et al. Reductions in alcohol and cocaine use following a group coping intervention for HIV-positive adults with childhood sexual abuse histories. Addiction. 2010;105:1942–51.PubMedCrossRef
81.
Sikkema KJ, Hansen NB, Kochman A, et al. Outcomes from a group intervention for coping with HIV/AIDS and childhood sexual abuse: reductions in traumatic stress. AIDS Behav. 2007;11:49–60.PubMedCrossRef
82.
Woolridge EW, Barton S, Samuel J, et al. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage. 2005;29:358–67.PubMedCrossRef
83.
Prentiss D, Power R, Balmas G, et al. Patterns of Marijuana use among patients with HIV/AIDS followed in a public health care setting. J Acquir Immune Defic Syndr. 2004;35:38–45.PubMedCrossRef
84.
de Jong BC, Prentiss D, McFarland W, et al. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. J Acquir Immune Defic Syndr. 2005;38:43–6.PubMedCrossRef
85.
Tucker JS, Burnam MA, Sherbourne CD, et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573–80.PubMedCrossRef
86.
Corless IB, Lindgren T, Holzemer W, et al. Marijuana effectiveness as an HIV self-care strategy. Clin Nurs Res. 2009;18:172–93.PubMedCrossRef
87.
Deitz E, Clum GA, Chung S, et al. Adherence to scheduled appointments among HIV-infected female youth in five U.S. cities. J Adolesc Health. 2010;46:278–83.CrossRef
88.
Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep. 2005;2:194–9.PubMedCrossRef
89.
Marquez C, Mitchell SJ, Hare CB, et al. Methamphetamine use, sexual activity, patient-provider communication, and medication adherence among HIV-infected patients in care, San Francisco 2004–2006. AIDS Care. 2009;21:575–82.PubMedCrossRef
90.
Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care. 2003;15:775–85.PubMedCrossRef
91.
McElhiney MC, Rabkin JG, Rabkin R, Nunes EV. Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+ gay men: a pilot study. Am J Drug Alcohol Abuse. 2009;35:34–7.PubMedCrossRef
92.
Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged ≥18 years—United States, 2009. Morbid Mortal Wkly Rep. 2010;59:1135–40.
93.
Fuster M, Estrada V, Fernandez-Pinilla MC, et al. Smoking cessation in HIV patients: rate of success and associated factors. HIV Med. 2009;10:614–9.PubMedCrossRef
94.
Webb MS, Vanable PA, Carey MP, Blair DC. Cigarette smoking among HIV+ men and women: examining health, substance use, and psychosocial correlates across the smoking spectrum. J Behav Med. 2007;30:371–83.PubMedCrossRef
95.
Lifson AR, Neuhaus J, Arribas JR, et al. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010;100:1896–903.PubMedCrossRef
96.
Jaquet A, Ekouevi DK, Aboubakrine M, et al. Tobacco use and its determinants in HIV-infected patients on antiretroviral therapy in West African countries. Int J Tuberc Lung Dis. 2009;13:1433–9.PubMed
97.
•• Feldman DN, Feldman JG, Greenblatt R, et al. CYP1A1 genotype modifies the impact of smoking on effectiveness of HAART among women. AIDS Educ Prev. 2009;21:81–93. This study showed that tobacco smoking may limit the effectiveness of ART by promoting HIV-1 gene expression. PubMedCrossRef
98.
Humfleet GL, Delucchi K, Kelley K, et al. Characteristics of HIV-positive cigarette smokers: a sample of smokers facing multiple challenges. AIDS Educ Prev. 2009;21:54–64.PubMedCrossRef
99.
Reynolds NR. Cigarette smoking and HIV: more evidence for action. AIDS Educ Prev. 2009;21:106–21.PubMedCrossRef
100.
Nahvi S, Cooperman NA. Review: the need for smoking cessation among HIV-positive smokers. AIDS Educ Prev. 2009;21:14–27.PubMedCrossRef
101.
Peretti-Watel P, Spire B, Lert F, et al. Drug use patterns and adherence to treatment among HIV-positive patients: evidence from a large sample of French outpatients (ANRS-EN12-VESPA 2003). Drug Alcohol Depend. 2006;82:S71–9.PubMedCrossRef
102.
Webb MS, Vanable PA, Carey MP, Blair DC. Medication adherence in HIV-infected smokers: the mediating role of depressive symptoms. AIDS Educ Prev. 2009;21:94–105.PubMedCrossRef
103.
Lloyd-Richardson EE, Stanton CA, Papandonatos GD, et al. Motivation and patch treatment for HIV+ smokers: a randomized trial. Addiction. 2009;104:1891–900.PubMedCrossRef
104.
Ingersoll KS, Cropsey KL, Heckman CJ. A test of motivational plus nicotine replacement interventions for HIV positive smokers. AIDS Behav. 2009;13:545–54.PubMedCrossRef
105.
Piper ME, Smith SS, Schlam TR, et al. Psychiatric disorders in smokers seeking treatment for tobacco dependence: relations with tobacco dependence and cessation. J Consult Clin Psychol. 2010;78:13–23.PubMedCrossRef
106.
Zvolensky M, Kotov R, Bonn-Miller M, et al. Anxiety sensitivity as a moderator of association between smoking status and panic-related processes in a representative sample of adults. J Psychiatr Res. 2008;42:69–77.PubMedCrossRef
107.
•• Pisu M, Cloud G, Austin S, et al. Substance abuse treatment in an urban HIV clinic: who enrolls and what are the benefits? AIDS Care. 2010;22:348–54. This study showed that substance abuse treatment alone may not promote improvements in immunity or viral load suppression.PubMedCrossRef
108.
Conway B, Prasad J, Reynolds R, et al. Directly observed therapy for the management of HIV-infected patients in a methadone program. Clin Infect Dis. 2004;38:S402–8.PubMedCrossRef
109.
Lucas GM, Weidle PJ, Hader S, Moore RD. Directly administered antiretroviral therapy in an urban methadone maintenance clinic: a nonrandomized comparative study. Clin Infect Dis. 2004;38:S409–13.PubMedCrossRef
110.
•• Berg KM, Litwin A, Li X, et al. Directly observed antiretroviral therapy improves adherence and viral load in drug users attending methadone maintenance clinics: a randomized controlled trial. Drug Alcohol Depend. 2011;113:192–9. This randomized controlled trial showed that directly administered ART in conjunction with methadone maintenance therapy promotes ART adherence and HIV viral suppression.PubMedCrossRef
111.
Lucas GM, Mullen BA, McCaul ME, et al. Adherence, drug use, and treatment failure in a methadone clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care STDS. 2007;21:564–74.PubMedCrossRef
112.
Ingersoll KS, Farrell-Carnahan L, Cohen-Filipic J, et al. A pilot randomized clinical trial of two medication adherence and drug use interventions for HIV+ crack cocaine users. Drug Alcohol Depend. 2011;116:177–87.PubMedCrossRef
113.
Daughters SB, Magidson JF, Schuster RM, Safren SA. Act healthy: a combined cognitive-behavioral depression and medication adherence treatment for HIV-infected substance users. Cogn Behav Pract. 2010;17:309–21.PubMedCrossRef
114.
O’Cleirigh C, Traeger L, Otto MW, et al. Medication adherence outcomes are mediated by treatment related changes in depression among a diverse HIV-infected sample in substance use treatment. Oral presentation at the International Association of Physicians in AIDS Care (IAPAC) 6th Annual International Conference on HIV Treatment and Prevention Adherence. Miami Beach, FL; May 22–24, 2011.
115.
Bush K, Kivlaham DR, McDonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158:1789–95.PubMedCrossRef
116.
Frank D, DeBenedetti AF, Volk RJ, et al. Effectiveness of the AUDIT-C as a screening test for alcohol misuse in three race/ethnic groups. J Gen Intern Med. 2008;23:781–7.PubMedCrossRef
117.
Bradley KA, DeBenedetti AF, Volk RJ, et al. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res. 2007;31:1208–17.PubMedCrossRef
118.
119.
120.
Carrier E, Yee T, Holzwart RA. Coordination between emergency and primary care physicians. Natl Inst Health Care Reform Res Brief. 2011;3:1–11.
121.
Bradford JB. The promise of outreach for engaging and retaining out-of-care persons in HIV medical care. AIDS Patient Care STDS. 2007;21:S85–91.PubMed
122.
Bradford JB, Coleman S, Cunningham W. HIV systems navigation: An emerging model to improve HIV care access. AIDS Prevention Care STDS. 21:S49-58
Metadata
Title
Substance Use: Impact on Adherence and HIV Medical Treatment
Authors
Adam Gonzalez
Jennifer Barinas
Conall O’Cleirigh
Publication date
01-12-2011
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 4/2011
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-011-0093-5

Other articles of this Issue 4/2011

Current HIV/AIDS Reports 4/2011 Go to the issue

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Promising Prevention Approaches: Tenofovir Gel and Prophylactic Use of Antiretroviral Medications

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Women and Vulnerability to HAART Non-Adherence: A Literature Review of Treatment Adherence by Gender from 2000 to 2011

Erratum

Erratum to: Management of Fat Accumulation in Patients with HIV Infection

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

Link to Slower Access to Care: What is the Stigma? An Indian Perspective

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

HIV-Related Research in Correctional Populations: Now is the Time

Behavioral Aspects of HIV Management (Ralph J. DiClemente and Jennifer Brown, Section Editors)

A Global Perspective on Complementary and Alternative Medicine Use Among People Living with HIV/AIDS in the Era of Antiretroviral Treatment
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits